PanNeoVaxIN™

Our mRNA cancer vaccine platform taps the power of neoantigens—unique tumor mutations that spark potent, precise immune responses. PanNeoVaxIN™ leverages population-relevant epitope prioritization, seamlessly incorporating safety markers, HLA diversity, and manufacturability into each design.

Key features:

• Pan-population epitope libraries guided by Indian and global prevalence data

• Modular mRNA constructs enabling multivalent vaccine cocktails

• Cost-efficient, GMP-ready formulations for broad deployment